AzTrials
AzTrials

Chronic Pelvic Pain SyndromePROM for CPPNCT06083597

Development of a Patient-reported Outcome Measure for Women With Chronic Pelvic Pain

An observational study of Chronic Pelvic Pain Syndrome and Pelvic Congestive Syndrome, run by Weill Medical College of Cornell University at 1 site in United States.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this study is to develop a patient questionnaire that can be utilized to assess the benefit of treatments of chronic pelvic pain in research studies. The information collected from a series of patient interviews will lead to the development of a questionnaire that accounts for the full impact of chronic… Read more about this study

Who is it for?
Ages 18 to 60 years, women onlyHealthy volunteers can take part
What is being tested?
Qualitative interview
How many people
55 participants
Where
1 siteUnited States
Study dates
1 Jul 2023to 31 Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Study population: Women with chronic pelvic pain (CPP) meeting the American College of Obstetricians and Gynecologists criteria.

Who may be able to join

  • Non-menopausal women ≥18 years old.
  • Women who are not menstruating because of ovarian suppression therapy for CPP are eligible.
  • CPP meeting the American College of Obstetricians and Gynecologists criteria.
  • Patient pain is primarily of pelvic and/or pelvic floor origin. Patient may experience other pain symptoms, including bowel, bladder, musculoskeletal, skin allodynia and hyperalgesia, or lower extremity venous or vulvar pain.
  • Imaging demonstrating multiple tortuous pelvic varicose veins > 5 mm in diameter in the ovarian, utero vaginal, and/or uterine arcuate venous plexus.
  • Imaging must be documented from trans vaginal ultrasound, trans abdominal ultrasound, magnetic resonance imaging, computed tomography, catheter venogram, or trans fundal pelvic venogram. If laparoscopic images are available to confirm veins this size, this would be acceptable as well.
Show all 22Show fewer
  • Venous contribution to CPP, as determined by clinical impression from a CPP specialist. Clinical impression will be based on the presence of the following symptoms and physical findings:
  • Symptoms: i. CPP increased with standing, walking, or lifting ii. CPP increased at the end of the day iii. CPP improved by laying down iv. Sexually provoked prolonged post-coital ache b. Physical findings: i. Adnexal tenderness on gentle bimanual exam ii. Tenderness at the ovarian point trans-abdominally iii. Tenderness of the uterus
  • Participant can read, communicate clearly, and understand English or Spanish.
  • Participant is willing and able to participate in an interview and complete questionnaires.
  • Participant is willing and able to provide informed consent.
  • Non-menopausal women ≥18 years old.
  • Women who are not menstruating because of ovarian suppression therapy for CPP are eligible.
  • CPP meeting the American College of Obstetricians and Gynecologists criteria.
  • Patient pain is primarily of pelvic and/or pelvic floor origin. Patient may experience other pain symptoms, including bowel, bladder, musculoskeletal, skin allodynia and hyperalgesia, or lower extremity venous or vulvar pain.
  • Imaging demonstrating multiple tortuous pelvic varicose veins > 5 mm in diameter in the ovarian, utero vaginal, and/or uterine arcuate venous plexus.
  • Imaging must be documented from trans vaginal ultrasound, trans abdominal ultrasound, magnetic resonance imaging, computed tomography, catheter venogram, or trans fundal pelvic venogram. If laparoscopic images are available to confirm veins this size, this would be acceptable as well.
  • Venous contribution to CPP, as determined by clinical impression from a CPP specialist. Clinical impression will be based on the presence of the following symptoms and physical findings:
  • Symptoms: i. CPP increased with standing, walking, or lifting ii. CPP increased at the end of the day iii. CPP improved by laying down iv. Sexually provoked prolonged post-coital ache b. Physical findings: i. Adnexal tenderness on gentle bimanual exam ii. Tenderness at the ovarian point trans-abdominally iii. Tenderness of the uterus
  • Participant can read, communicate clearly, and understand English or Spanish.
  • Participant is willing and able to participate in an interview and complete questionnaires.
  • Participant is willing and able to provide informed consent.

Who cannot join

  • Pain symptoms should primarily be of pelvic and/or pelvic floor origin (inclusion criteria #3 above). Pain should not be exclusively low back, hips, symphysis, allodynia or hyperalgesia of the skin, or from varicose veins of the vulvar and/or lower extremities.
  • Pain thought primarily to be due to endometriosis, pelvic floor myalgia, a musculoskeletal etiology, irritable bowel disease, or painful bladder syndrome/interstitial cystitis.
  • Obvious endometriosis based on physical exam or laparoscopy findings.
  • Patients previously treated with a technically successful surgery or vascular procedure for a venous disorder of the pelvis or renal vein.
  • Participant has any clinically relevant medical condition (e.g., severe co morbid condition, severe mental illness, severe visual or auditory impairment, or cognitive impairment) that, in the opinion of the investigator, would interfere with participating in an interview and/or completing the study procedures
  • Second phase of study evaluation women with non-venous origin chronic pelvic pain
Show all 11Show fewer
  • Pain symptoms should primarily be of pelvic and/or pelvic floor origin (inclusion criteria #3 above). Pain should not be exclusively low back, hips, symphysis, allodynia or hyperalgesia of the skin, or from varicose veins of the vulvar and/or lower extremities.
  • Pain thought primarily to be due to endometriosis, pelvic floor myalgia, a musculoskeletal etiology, irritable bowel disease, or painful bladder syndrome/interstitial cystitis.
  • Obvious endometriosis based on physical exam or laparoscopy findings.
  • Patients previously treated with a technically successful surgery or vascular procedure for a venous disorder of the pelvis or renal vein.
  • Participant has any clinically relevant medical condition (e.g., severe co morbid condition, severe mental illness, severe visual or auditory impairment, or cognitive impairment) that, in the opinion of the investigator, would interfere with participating in an interview and/or completing the study procedures

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site
  • Weill Cornell Medicine

    New York, New York, 10065

Other trials in United States

About this study

Official title: Development of a Patient-reported Outcome (PRO) Measure for Women With Chronic Pelvic Pain (CPP)

The purpose of this study is to develop a patient questionnaire that can be utilized to assess the benefit of treatments of chronic pelvic pain in research studies.

The information collected from a series of patient interviews will lead to the development of a questionnaire that accounts for the full impact of chronic pelvic pain from an affected woman's perspective.

Read the detailed description

The purpose of this study is to develop a patient-reported outcome (PRO) instrument that can be utilized as an efficacy endpoint to assess medical and surgical treatments of chronic pelvic pain (CPP) in comparative outcomes research.

This instrument will be developed consistent with Food and Drug Administration (FDA) guidance to be appropriate as an efficacy measurement in a clinical trial. The development of such a PRO measure is iterative, and this research protocol includes the qualitative research to develop a draft measure and document content validity. Content validity is first assessed through concept elicitation interviews, followed by cognitive interviews.

Patients who are eligible and consent to participate will:

  1. complete a series of standardized health questionnaires
  2. participate in an interview with a scientist who is an expert at developing this kind of PRO instrument who will ask patients about the impacts of their COO on their overall health and well being.

The information collected from a series of these interviews will lead to the development of a draft questionnaire which will then be reviewed with additional women with similar causes of CPP as well as with women with other causes of CPP to determine its usability and accuracy at assessing the impacts of CPP on their health and well being.

A final version of the PROM instrument will then be shared with women with CPP before and after any treatment to determine its ability to identify changes in their health and wellbeing.

Being tested
Qualitative interview

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Qualitative interviewOther

    Qualitative interviews will be performed on women with chronic pelvic pain of venous origin.

Study groups in NCT06083597
Study groupRoleWhat they receive
Chronic pelvic pain of venous originWomen who are thought to have chronic pelvic pain of venous origin will be interviewed to determine the impacts of their pain on physical, social and emotional aspects of their health and well being.
Receives: Other: Qualitative interview
Chronic pelvic pain of non-venous originWomen who are thought to have chronic pelvic pain of a non-venous origin will be interviewed to determine the impacts of their pain on physical, social and emotional aspects of their health and well being. They will be asked of the concepts identified by the women with venous origin CPP apply to them and if the impacts of the pain are similar or differ.
Receives: Other: Qualitative interview

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Phase 1 qualitative concept elicitation interview

    Phase 1 qualitative interview about VO-CPP (Chronic pelvic pain originating from venous contribution) signs, symptoms, and impacts, from which a novel VO-CPP questionnaire (PeVD HRQoL) will be drafted, and ultimately assessed for content validity in the Phase 2 interviews. This Phase 1 interview will be conducted with subjects with VO-CPP.

    Measured: 1 month

Secondary outcomes (3)
  1. Phase 2 Qualitative cognitive interview

    Phase 2 qualitative interview will include questions about item clarity, how the participants interpret the items, ease of completing the PeVD HRQoL questions, questionnaire comprehensiveness, and the appropriateness of the questionnaire format and response scales. This Phase 2 interview will be conducted with subjects with VO-CPP.

    Measured: 1 month

  2. Phase 2 qualitative open-ended concept elicitation questions

    Phase 2 qualitative open-ended concept elicitation questions. This Phase 2 interview will be conducted with subjects with chronic pelvic pain originating from non-venous causes (NVO-CCP).

    Measured: 1 month

  3. Phase 2 qualitative cognitive interview

    Phase 2 qualitative interview about the content validity of the novel questionnaire, PeVD HRQoL, with subjects with chronic pelvic pain originating from non-venous causes (NVO-CCP).

    Measured: 1 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Oct 2023
  2. Study start1 Jul 2023
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Cross-sectional
Enrolment
55 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06083597
Sponsor's protocol ID
23-02025699
Acronym
PROM for CPP
Status last verified
Dec 2025
First submitted
31 Aug 2023
Last updated
18 Dec 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The study protocol, informed consent forms, de-identified data, analytic process and the clinical study report will be available for other researchers. The final patient reported outcome instrument will be made available for use by any investigator for clinical research by the study funder SIR Foundation

Questions about this trial

What is this clinical trial studying?

An observational study of Chronic Pelvic Pain Syndrome and Pelvic Congestive Syndrome, run by Weill Medical College of Cornell University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 22 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 18 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Phase 1 qualitative concept elicitation interview (time frame: 1 month). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in